Vetoquinol SA
VETO
Company Profile
Business description
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
Contact
Magny-Vernois
BP 189
Lure cedex70204
FRAT: +33 384625555
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
2,497
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks
Chart of the Week: US equity market trading at an attractive discount
The latest from our Chief US Market Strategist.
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.90 | 43.80 | 0.48% |
| CAC 40 | 8,198.83 | 65.04 | -0.79% |
| DAX 40 | 23,793.43 | 287.20 | -1.19% |
| Dow JONES (US) | 47,909.92 | 1,325.46 | 2.85% |
| FTSE 100 | 10,582.78 | 26.10 | -0.25% |
| HKSE | 25,752.40 | 140.62 | -0.54% |
| NASDAQ | 22,634.99 | 617.14 | 2.80% |
| Nikkei 225 | 55,895.32 | 413.10 | -0.73% |
| NZX 50 Index | 13,273.81 | 19.87 | 0.15% |
| S&P 500 | 6,782.81 | 165.96 | 2.51% |
| S&P/ASX 200 | 8,973.20 | 57.80 | 0.65% |
| SSE Composite Index | 3,966.17 | 28.83 | -0.72% |